content: <PAGE>  1
                        SECURITIES AND EXCHANGE COMMISSION
  
                             Washington, D.C.  20549
  
  
  
                                     Form 8-K
  
  
  
                                  CURRENT REPORT
  
       Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
  
                                 August 22, 2001
                 -------------------------------------------------
                 (Date of Report: Date of earliest event reported)
  
  
                           IMMUNOTECHNOLOGY CORPORATION
              ------------------------------------------------------
        (Exact name of registrant as specified in its charter)
  
  
           DELAWARE                    0-24641             84-1016435
  ---------------------------- -----------------------  --------------------
  (State or other jurisdiction (Commission File Number) (IRS Employer ID No.)
   of incorporation)
  
  
  
                     1661 Lakeview Circle, Ogden, Utah  84403
                  ------------------------------------------------
                      (Address of principal executive office)
  
  
  
  Registrant's telephone number, including area code: (801) 399-3632
                                                      --------------
  
                                Not Applicable
       ---------------------------------------------------------------------
          (Former name or former address, if changed since last report)
  
  
  
  
  
  
  
  
  
  
  
                      
  <PAGE>
  <PAGE> 2
                                ITEM 5. OTHER EVENTS
  
  1. Issuance of Shares on Conversion of Promissory Note
  ------------------------------------------------------
  On August 22, 2001, our board of directors approved the issuance of an
  aggregate of 2,050,731 shares of our common stock to Mark A. Scharmann, our
  President and David Knudson, our Secretary/Treasurer. Mr. Scharmann was issued
  1,036,789 shares in exchange for the conversion of $32,399.67 in principle and
  accrued interest under a demand note.  Mr. Knudson was issued 1,013,942 shares
  in exchange for the conversion of $31,685.79 in principle and accrued interest
  under a demand note. Prior to the conversion of the demand note we had
  6,000,000 shares of its common stock issued and outstanding. After giving
  effect to the issuance of the conversion shares to Messrs. Scharmann and
  Knudson, we Registrant have 8,050,731 shares of common stock issued and
  outstanding.  The shares issued in the foregoing transaction constitute
  restricted securities issued pursuant to section 4(2) of the Securities Act of
  1933, as amended.
  
  
  (c)  Exhibits.  The following exhibits are included as part of this report:
  
       None.
  
                              SIGNATURES
  
  Pursuant to the requirements of the Securities Exchange Act of 1934, as
  amended, the Registrant has duly caused this report to be signed on its behalf
  by the undersigned hereunder duly authorized.
  
                                           IMMUNOTECHNOLOGY CORPORATION
  
  Date: September 6, 2001                  /S/David Knudson, Secretary/Treasurer
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "f8k01aug.txt", "description": "CURRENT REPORT AUGUST 22, 2001", "secsgml_size_bytes": 3021}]
metadata_filer: {"company-data": {"conformed-name": "IMMUNOTECHNOLOGY CORP", "cik": "0000789097", "assigned-sic": "6770", "irs-number": "841016435", "state-of-incorporation": "DE", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-24641", "film-number": "1732364"}, "business-address": {"street1": "1661 LAKEVIEW CIRCLE", "city": "OGDEN", "state": "UT", "zip": "84403", "phone": "8013993632"}, "former-company": [{"former-conformed-name": "IMMUNOTECHNOLOGY LABORATORIES INC", "date-changed": "19900503"}, {"former-conformed-name": "LJC CORP", "date-changed": "19891025"}]}
text: 1
                        SECURITIES AND EXCHANGE COMMISSION
  
                             Washington, D.C.  20549
  
                                     Form 8-K
  
                                  CURRENT REPORT
  
       Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
  
                                 August 22, 2001
                 -------------------------------------------------
                 (Date of Report: Date of earliest event reported)
  
                           IMMUNOTECHNOLOGY CORPORATION
              ------------------------------------------------------
        (Exact name of registrant as specified in its charter)
  
           DELAWARE                    0-24641             84-1016435
  ---------------------------- -----------------------  --------------------
  (State or other jurisdiction (Commission File Number) (IRS Employer ID No.)
   of incorporation)
  
                     1661 Lakeview Circle, Ogden, Utah  84403
                  ------------------------------------------------
                      (Address of principal executive office)
  
  Registrant's telephone number, including area code: (801) 399-3632
                                                      --------------
  
                                Not Applicable
       ---------------------------------------------------------------------
          (Former name or former address, if changed since last report)
  2
                                ITEM 5. OTHER EVENTS
  
  1. Issuance of Shares on Conversion of Promissory Note
  ------------------------------------------------------
  On August 22, 2001, our board of directors approved the issuance of an
  aggregate of 2,050,731 shares of our common stock to Mark A. Scharmann, our
  President and David Knudson, our Secretary/Treasurer. Mr. Scharmann was issued
  1,036,789 shares in exchange for the conversion of $32,399.67 in principle and
  accrued interest under a demand note.  Mr. Knudson was issued 1,013,942 shares
  in exchange for the conversion of $31,685.79 in principle and accrued interest
  under a demand note. Prior to the conversion of the demand note we had
  6,000,000 shares of its common stock issued and outstanding. After giving
  effect to the issuance of the conversion shares to Messrs. Scharmann and
  Knudson, we Registrant have 8,050,731 shares of common stock issued and
  outstanding.  The shares issued in the foregoing transaction constitute
  restricted securities issued pursuant to section 4(2) of the Securities Act of
  1933, as amended.
  
  (c)  Exhibits.  The following exhibits are included as part of this report:
  
       None.
  
                              SIGNATURES
  
  Pursuant to the requirements of the Securities Exchange Act of 1934, as
  amended, the Registrant has duly caused this report to be signed on its behalf
  by the undersigned hereunder duly authorized.
  
                                           IMMUNOTECHNOLOGY CORPORATION
  
  Date: September 6, 2001                  /S/David Knudson, Secretary/Treasurer